Initial combinations of empagliflozin and metformin in patients with type 2 diabetes

被引：0
|
作者：
Hadjadj, S. [1 ,2 ]
Jelaska, A. [3 ]
Zhang, S. [3 ]
Meinicke, T. [4 ]
Woerle, H. J. [5 ]
Broedl, U. C. [5 ]
机构：
[1] Ctr Hosp Univ Poitiers, Poitiers, France
[2] INSERM, CIC 1402, Poitiers, France
[3] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[5] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
来源：
DIABETOLOGIA | 2015年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
733
引用
收藏
页码：S350 / S350
页数：1
相关论文
共 50 条
  • [21] Initial sitagliptin plus metformin demonstrated to be effective in patients with type 2 diabetes
    不详
    FORMULARY, 2007, 42 (09) : 562 - 562
  • [22] Empagliflozin twice daily versus once daily as add-on to metformin in patients with type 2 diabetes
    Ross, S.
    Hamer, C.
    Cescutti, J.
    Meinicke, T.
    Woerle, H. J.
    Broedl, U. C.
    DIABETOLOGIA, 2014, 57 : S345 - S345
  • [23] Metformin as Initial Oral Therapy in Type 2 Diabetes
    Stern, Rachel J.
    Murphy, Elizabeth J.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (24): : 2484 - 2485
  • [24] Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes
    Kohler, Sven
    Salsali, Afshin
    Hantel, Stefan
    Kaspers, Stefan
    Woerle, Hans J.
    Kim, Gabriel
    Broedl, Uli C.
    CLINICAL THERAPEUTICS, 2016, 38 (06) : 1299 - 1313
  • [25] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans-Juergen
    Broedl, Uli C.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [26] Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study
    Lim, Soo
    Sohn, Minji
    Florez, Jose C.
    Nauck, Michael A.
    Ahn, Jiyoung
    NUTRIENTS, 2023, 15 (01)
  • [27] Safety and tolerability of empagliflozin in patients with Type 2 diabetes
    Salsali, A.
    Kohler, S.
    Hantel, S.
    Kim, G.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2016, 33 : 66 - 66
  • [28] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2014, 63 : A278 - A278
  • [29] Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes
    Tesfaye, Helen
    Paik, Julie M.
    Roh, Miin
    Htoo, Phyo T.
    Zakoul, Heidi
    Schmedt, Niklas
    Koeneman, Lisette
    Wexler, Deborah J.
    Patorno, Elisabetta
    JAMA OPHTHALMOLOGY, 2025, 143 (01) : 62 - 71
  • [30] Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin
    Blevins, Thomas
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (05) : 789 - 793
12345